Aera Therapeutics raises $193M to develop genetic therapies

 

Aera Therapeutics has raised a $193M Series A and B combined funding round to develop genetic therapies.  ARCH Venture Partners, GV, and Lux Capital were the lead investors. The platform, based on endogenous human proteins, is being developed to expand the reach of genetic medicines to different tissues and applications in order to benefit more patients across more disease areas. Aera's core team comprises researchers that work in institutions such as Harvard, MIT, Johns Hopkins, etc. The company aims to use the funds to expand its operations and boost its R&D. The company is based in Boston, Massachusetts.